Highlights of This Issue

SPECIAL FEATURES

CCR Translations

5217 Overcoming Antiangiogenic Resistance
James C. Yao and Alexandria Phan
See article p. 5299

CCR Perspectives in Drug Approval

5220 The European Medicines Agency: An Overview of Its Mission, Responsibilities, and Recent Initiatives in Cancer Drug Regulation
Francesco Pignatti, Iordanis Gravanis, Ralf Herold, Spiros Vamvakas, Bertil Jonsson, and Michel Marty

Molecular Pathways

5226 Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis
Michele De Palma and Luigi Naldini

5233 Prostate Cancer Immunotherapy
Kenneth F. May, Jr., James L. Gulley, Charles G. Drake, Glenn Dranoff, and Philip W. Kantoff

Special Report

5239 SWOG Cooperative Group
Biorepository Resource: Access for Scientific Research Studies
Carolyn J. Hoban, Wilbur A. Franklin, Kenneth J. Kopecky, and Laurence H. Baker

Review

5247 Prognostic Immune Markers in Non–Small Cell Lung Cancer
Kei Suzuki, Stefan S. Kachala, Kyuichi Kadota, Rongtai Shen, Qianxing Mo, David G. Beer, Valerie W. Rusch, William D. Travis, and Prasad S. Adusumilli

HUMAN CANCER BIOLOGY

5257 Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer

5268 Clonal Relationship of Classical Hodgkin Lymphoma and its Recurrences
Ellen C. Obermann, Nadine Mueller, Alexander Ruffle, Thomas Menter, Esther Mueller-Garamvolgyi, Gieri Cathomas, Stephan Dirnhofer, and Alexandar Tzankov

5275 FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo
Rachel Sharpe, Alex Pearson, Maria T. Herrera-Abreu, Damian Johnson, Alan Mackay, Jonathan C. Welti, Rachael Natrajan, Andrew R. Reynolds, Jorge S. Reis-Filho, Alan Ashworth, and Nicholas C. Turner

5287 Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis
Sharanjot Saini, Shahana Majid, Soichiro Yamamura, Laura Tabatabai, Seong O. Suh, Varahram Shahrzadi, Yi Chen, Guoren Deng, Yuichiro Tanaka, and Rajvir Dahiya

CANCER THERAPY: PRECLINICAL

5299 Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition
Elizabeth Allen, Ian B. Walters, and Douglas Hanahan
See commentary p. 5217
In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells

Dharminder Chauhan, Ze Tian, Bin Zhou, Deborah Kuhn, Robert Orlowski, Noopur Raje, Paul Richardson, and Kenneth C. Anderson

Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with P38/mTOR Target Inhibition but with [18F]FLT Uptake

Thorsten Fuereder, Thomas Wanek, Pamina Pflegerl, Agnes Jaeger-Lansky, Doris Hoeffmayer, Sabine Strommer, Claudia Kuntner, Friedrich Wrb, Johannes Wazerowa, Michael Heyna, Markus Miller, Oliver Langer, and Volker Wacheck

Regression of Glioma in Rat Models by Intranasal Application of Parvovirus H-1

Irina Kiprianova, Nadja Thomas, Ali Ayache, Manuel Fischer, Barbara Leuchs, Michèle Klein, Jean Rommelaere, and Jörg R. Schlehofer

Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice

Christopher A. Klebanoff, Luca Gattinoni, Douglas C. Palmer, Pawel Muranski, Yun Ji, Christian S. Hinrichs, Zachary A. Borman, Sid P. Kerkar, Christopher D. Scott, Steven E. Finkielstein, Steven A. Rosenberg, and Nicholas P. Restifo

PM02734 (Elisidepsin) Induces Caspase-Independent Cell Death Associated with Features of Autophagy, Inhibition of the Akt/mTOR Signaling Pathway, and Activation of Death-Associated Protein Kinase

Yi-He Ling, Miguel Aracil, Yiyu Zou, Ziqiang Yuan, Bo Lu, José Jimeno, Ana Maria Cuervo, and Roman Perez-Soler

Targeting Src in Mucinous Ovarian Carcinoma


Lupeol, a Novel Androgen Receptor Inhibitor: Implications in Prostate Cancer Therapy

Hifzur Rahman Siddique, Shrawan Kumar Mishra, R. Jeffery Karnes, and Mohammad Saleem

Induction of HLA-DP4–Restricted Anti-Survivin Th1 and Th2 Responses Using an Artificial Antigen-Presenting Cell

Makito Tanaka, Marcus O. Butler, Sascha Ansén, Osamu Imataki, Alla Berezovskaya, Lee M. Nadler, and Naoto Hirano

Resveratrol Selectively Induces DNA Damage, Independent of Smad4 Expression, In Its Efficacy against Human Head and Neck Squamous Cell Carcinoma

Alpna Tyagi, Mallikarjunu Ga, Takenori Takahata, Barbara Frederic, Chapla Agarwal, Sunitha Sirtiwardana, Rajesh Agarwal, and Robert A. Scalfani

Role of Smac in Determining the Chemotherapeutic Response of Esophageal Squamous Cell Carcinoma

Yang Xu, Lanping Zhou, Jing Huang, Fang Liu, Jian Yu, Qimin Zhan, Lin Zhang, and Xiaohang Zhao

Antitumor Activity of YM155, a Selective Small-Molecule Survivin Suppressor, Alone and in Combination with Docetaxel in Human Malignant Melanoma Models

Kentaro Yamanaka, Takahito Nakahara, Tomohiro Yamauchi, Aya Kita, Masahiro Takeuchi, Fumiko Kiyonaga, Naoki Kaneko, and Masao Sasamata

Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90

Pramod P. Mehta, Pamela Whalen, Sangita M. Baxi, Pei-Pei Kung, Shinji Yamazaki, and Min-Jean Yin

Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group

Membranous Expression of Ectodomain Isoforms of the Epidermal Growth Factor Receptor Predicts Outcome after Chemoradiotherapy of Lymph Node–Negative Cervical Cancer
Cathinka Halle, Malin Lando, Debbie Hege Svendsrud, Trevor Clancy, Marit Holden, Kolbein Sundfør, Gunnar B. Kristensen, Ruth Holm, and Heidi Lyng

XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck

Correction: Regulation of HMGA1 Expression by MicroRNA-296 Affects Prostate Cancer Growth and Invasion

Correction: Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Immunohistochemical analysis confirmed that YM155 reduced survivin protein levels, whereas docetaxel treatment increased p34 Thr-survivin protein at G2/M mitotic arrest. Furthermore, the concomitant treatment YM155 apparently decreased the docetaxel-induced survivin upregulation below the basal level in SK-MEL-5 human malignant melanoma cell. For further details, please see Yamanaka and colleagues on page 5423 in this issue.